{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:58:04Z","timestamp":1793397484295,"version":"4.5.0"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"152","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,4,28]]},"published-print":{"date-parts":[[2019,6,30]]},"abstract":"<jats:p>Over the past few decades, treatment of multidrug-resistant (MDR)\/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20\u201324\u2005months), toxicity, costs and sub-optimal outcomes.<\/jats:p><jats:p>After over 40\u2005years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-\/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9\u201310\u2005months.<\/jats:p><jats:p>The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.<\/jats:p>","DOI":"10.1183\/16000617.0035-2019","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T13:06:24Z","timestamp":1559135184000},"page":"190035","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":134,"title":["Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives"],"prefix":"10.1183","volume":"28","author":[{"given":"Emanuele","family":"Pontali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario C.","family":"Raviglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-574X","authenticated-orcid":false,"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"2024102403394255000_28.152.190035.1","unstructured":"World Health Organization. Global Tuberculosis Report 2018 . Geneva, World Health Organization, 2018."},{"key":"2024102403394255000_28.152.190035.2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MCP.0000000000000477","article-title":"Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management","volume":"24","author":"Pontali","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"2024102403394255000_28.152.190035.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016"},{"key":"2024102403394255000_28.152.190035.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu619"},{"key":"2024102403394255000_28.152.190035.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382301"},{"key":"2024102403394255000_28.152.190035.6","unstructured":"World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB) . Geneva, World Health Organization, 2000."},{"key":"2024102403394255000_28.152.190035.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2002.00960.x"},{"key":"2024102403394255000_28.152.190035.8","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis . Geneva, World Health Organization, 2006."},{"key":"2024102403394255000_28.152.190035.9","unstructured":"World Health Organization. The STOP-TB strategy . Geneva, World Health Organization, 2006."},{"key":"2024102403394255000_28.152.190035.10","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 . Geneva, World Health Organization, 2008."},{"key":"2024102403394255000_28.152.190035.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073611"},{"key":"2024102403394255000_28.152.190035.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2024102403394255000_28.152.190035.13","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"2024102403394255000_28.152.190035.14","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100"},{"key":"2024102403394255000_28.152.190035.15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"2024102403394255000_28.152.190035.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.10.021"},{"key":"2024102403394255000_28.152.190035.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02309-2016"},{"key":"2024102403394255000_28.152.190035.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00463-2017"},{"key":"2024102403394255000_28.152.190035.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209841"},{"key":"2024102403394255000_28.152.190035.20","doi-asserted-by":"crossref","first-page":"e0187211","DOI":"10.1371\/journal.pone.0187211","article-title":"Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide","volume":"12","author":"Ngabonziza","year":"2017","journal-title":"PLoS One"},{"key":"2024102403394255000_28.152.190035.21","doi-asserted-by":"crossref","unstructured":"Sun F , Li Y , Chen Y , et\u00a0al. Introducing molecular testing of pyrazinamide susceptibility improves MDR-TB treatment outcomes: a prospective cohort study. Eur Respir J 2018: 1801770.","DOI":"10.1183\/13993003.01770-2018"},{"key":"2024102403394255000_28.152.190035.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02445-2016"},{"key":"2024102403394255000_28.152.190035.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00387-2017"},{"key":"2024102403394255000_28.152.190035.24","doi-asserted-by":"crossref","unstructured":"Hewison C , Ferlazzo G , Avaliani Z , et\u00a0al. Six-month response to delamanid treatment in MDR-TB patients. Emerg Infect Dis 2017; 23: https:\/\/doi.org\/10.3201\/eid2310.170468.","DOI":"10.3201\/eid2310.170468"},{"key":"2024102403394255000_28.152.190035.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00934-2018"},{"key":"2024102403394255000_28.152.190035.26","doi-asserted-by":"crossref","unstructured":"Zhao Y , Fox T , Manning K , et\u00a0al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study. Clin Infect Dis 2018; https:\/\/doi.org\/10.1093\/cid\/ciy727.","DOI":"10.1093\/cid\/ciy727"},{"key":"2024102403394255000_28.152.190035.27","doi-asserted-by":"crossref","unstructured":"Ndjeka N , Schnippel K , Master I , et\u00a0al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J 2018: 1801528.","DOI":"10.1183\/13993003.01528-2018"},{"key":"2024102403394255000_28.152.190035.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"2024102403394255000_28.152.190035.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01462-2017"},{"key":"2024102403394255000_28.152.190035.30","doi-asserted-by":"crossref","unstructured":"Monedero-Recuero I , Hernando-Marrupe L , S\u00e1nchez-Montalv\u00e1 A , et\u00a0al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int J Tuberc Lung Dis 2018; https:\/\/doi.org\/10.5588\/ijtld.18.0423.","DOI":"10.5588\/ijtld.18.0423"},{"key":"2024102403394255000_28.152.190035.31","unstructured":"World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB) . Geneva, World Health Organization, 2018."},{"key":"2024102403394255000_28.152.190035.32","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment . Geneva, World Health Organization, 2019."},{"key":"2024102403394255000_28.152.190035.33","doi-asserted-by":"crossref","unstructured":"Global Tuberculosis Network (GTN). Evolution of programmatic definitions used in tuberculosis prevention and care. Clin Infect Dis 2018; https:\/\/doi.org\/10.1093\/cid\/ciy990.","DOI":"10.1093\/cid\/ciy990"},{"issue":"Suppl. 2","key":"2024102403394255000_28.152.190035.34","first-page":"S69","article-title":"Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid","volume":"22","author":"Conradie","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403394255000_28.152.190035.35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S1473-3099(18)30496-1","article-title":"Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study","volume":"18","author":"Makhado","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024102403394255000_28.152.190035.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00142914"},{"key":"2024102403394255000_28.152.190035.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30190-6"},{"key":"2024102403394255000_28.152.190035.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33731-1"},{"key":"2024102403394255000_28.152.190035.39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01163-2018"},{"key":"2024102403394255000_28.152.190035.40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/s1806-37562018000000279","article-title":"Global TB Network: working together to eliminate tuberculosis","volume":"44","author":"Silva","year":"2018","journal-title":"J Bras Pneumol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0035-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:00:59Z","timestamp":1740373259000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0035-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":40,"journal-issue":{"issue":"152","published-online":{"date-parts":[[2019,5,29]]},"published-print":{"date-parts":[[2019,6,30]]}},"alternative-id":["10.1183\/16000617.0035-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0035-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]}}}